NONEXCLUSIVE LICENSE AGREEMENT FACTOR IX VECTOR PRODUCTION TECHNOLOGYAgreement • June 29th, 2020 • Freeline Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT is entered into as of 24 March 2017 (the “Effective Date”) by and between St. Jude Children’s Research Hospital, a Tennessee not for profit corporation having a place of business at 262 Danny Thomas Place, Memphis, Tennessee 38105 (hereinafter “St. Jude”) and Freeline Therapeutics Limited, a limited liability company having a place of business at 215 Euston Road, London NW1 2BE (hereinafter “Licensee”).
AMENDMENT #1 TO THE NONEXCLUSIVE LICENSE AGREEMENT FACTOR IX VECTOR PRODUCTION TECHNOLOGYNonexclusive License Agreement • June 29th, 2020 • Freeline Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • New York
THIRD DEED OF AMENDMENT AND TERMINATION between UCL BUSINESS LTD and FREELINE THERAPEUTICS LIMITEDFreeline Therapeutics Holdings LTD • June 29th, 2020 • Biological products, (no disgnostic substances)
DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTDevelopment and Manufacturing Services Agreement • June 29th, 2020 • Freeline Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • New York
This DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (this “Agreement”), effective as of this 6th day of October, 2017 (the “Effective Date”), between, Freeline Therapeutics Limited (“Customer”), having its principal place of business at 215 Euston Road, London NW1 2BE, UK, and Brammer Bio MA, LLC, a Delaware limited liability company with offices at 250 Binney Street, Cambridge, MA 02142 (“Brammer”). Customer and Brammer are referred to herein each as a “Party” and collectively as the “Parties”.
Services AgreementServices Agreement • June 29th, 2020 • Freeline Therapeutics Holdings LTD • Biological products, (no disgnostic substances)
This services agreement, hereafter referred to as the “Agreement”, is entered into on 11th OCT. 2016 (the “Effective Date”) by and between
Certain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.Collaboration Agreement • June 29th, 2020 • Freeline Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • England and Wales
Biopharma Services Agreement [**] MCB & WCB manufacturing & releaseFreeline Therapeutics Holdings LTD • June 29th, 2020 • Biological products, (no disgnostic substances)
NOVASEP offers you a unique combination of services and advanced technologies for producing and purifying your biopharmaceuticals, from laboratory to industrial scale:
Certain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.Freeline Therapeutics Holdings LTD • June 29th, 2020 • Biological products, (no disgnostic substances)
FREELINE THERAPEUTICS LIMITED, a company incorporated in England and Wales (Company No. 09500073) with registered office address at Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Herts, SG1 2FX, United Kingdom, hereafter referred as “FREELINE”,
Certain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.Freeline Therapeutics Holdings LTD • June 29th, 2020 • Biological products, (no disgnostic substances)
